Work

Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study

Year: 2022

Type: erratum

Abstract: When this abstract was originally published, it contained the following erroneous text: “Both stratum 2 (pilocytic astrocytoma [PA] without common BRAF aberration) and stratum 5 (non-pilocytic astrocytoma with BRAF aberration) met response criteria for expansion (> 2 objective responses in 16 patients), and accrual to a total of 25 patients on each stratum is ongoing.” This should have appeared as: ”Stratum 5 (non-pilocytic astrocytoma with BRAF aberration) met response criterion for expansion (≥ 2 objective responses in 16 patients) and accrual to a total goal of 25 patients is ongoing. Stratum 2 (pilocytic astrocytoma [PA] without common BRAF aberration) has not met this same criterion for expansion, and accrual to a goal of 16 patients in Simon Stage 1 is ongoing.” The error occurred due an incorrect stratification of a subject. This subject had achieved a partial response, but a recent review of the data revealed that the subject should have been assigned to stratum 6 (indeterminate BRAF status) rather than to stratum 2. These details have been corrected only in this corrigendum to preserve the published version of record.

Source: Neuro-Oncology

DOI: 10.1093/neuonc/noac029